Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany;
Molecular Organization of the Brain, Institute for Neuroscience and Medicine, Jülich, Germany.
J Nucl Med. 2024 Jun 3;65(6):952-955. doi: 10.2967/jnumed.123.265930.
We used a new data-driven methodology to identify a set of reference regions that enhanced the quantification of the SUV ratio of the second-generation tau tracer 2-(2-([F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([F]PI-2620) in a group of patients clinically diagnosed with 4-repeat tauopathy, specifically progressive supranuclear palsy or cortical basal syndrome. The study found that SUV ratios calculated using the identified reference regions (i.e., fusiform gyrus and crus-cerebellum) were significantly associated with symptom severity and disease duration. This establishes, for the first time to our knowledge, the suitability of [F]PI-2620 for tracking disease progression in this 4-repeat disease population. This is an important step toward increased clinical utility, such as patient stratification and monitoring in disease-modifying treatment trials. Additionally, the applied methodology successfully optimized reference regions for automated detection of brain imaging tracers. This approach may also hold value for other brain imaging tracers.
我们使用一种新的数据驱动方法来确定一组参考区域，这些区域可以增强第二代 tau 示踪剂 2-(2-([F]氟代)吡啶-4-基)-9H-吡咯并[2,3-b:4,5-c']二吡啶([F]PI-2620)的 SUV 比值在一组临床诊断为 4 重复 tau 病的患者中的定量，特别是进行性核上性麻痹或皮质基底节综合征。研究发现，使用所确定的参考区域（即梭状回和小脑脚）计算的 SUV 比值与症状严重程度和疾病持续时间显著相关。这首次确立了[F]PI-2620 在追踪该 4 重复疾病人群疾病进展方面的适用性。这是提高临床实用性的重要一步，例如在疾病修饰治疗试验中对患者进行分层和监测。此外，所应用的方法成功地优化了参考区域，用于自动检测脑成像示踪剂。这种方法对于其他脑成像示踪剂也可能具有价值。
